ArticleOncogene2006
ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.International journal of molecular sciences · 2021Pooled it
- Contributions of ADAM12 via HB-EGF/EGFR signaling cascades to EMT and cancer progression in pancreas.Molecular and clinical oncology · 2026Article
- Depletion of slow-cycling PDGFRαNature immunology · 2023Article
- Methylation across the central dogma in health and diseases: new therapeutic strategies.Signal transduction and targeted therapy · 2023Review
- Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.BMC cancer · 2022Article
- A Disintegrin and Metalloprotease 12 Promotes Tumor Progression by Inhibiting Apoptosis in Human Colorectal Cancer.Cancers · 2021Article
- Aberrant Methylation of Tumour Suppressor Gene ADAM12 in Chronic Lympocytic Leukemia Patients: Application of Methylation Specific-PCR Technique.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- ADAM12 silencing promotes cellular apoptosis by activating autophagy in choriocarcinoma cells.International journal of oncology · 2020Article
- Genes associated with bowel metastases in ovarian cancer.Gynecologic oncology · 2019Article
- Genetic screens reveal mechanisms for the transcriptional regulation of tissue-specific genes in normal cells and tumors.Nucleic acids research · 2019Article
- ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.Oncogenesis · 2018Article
- TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.Cell biology international · 2018Article
- ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.Molecular cancer research : MCR · 2017Article
- ADAM12 induction by Twist1 promotes tumor invasion and metastasis via regulation of invadopodia and focal adhesions.Journal of cell science · 2017Article
- Article
- Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2016Review
- ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.Carcinogenesis · 2015Article
- Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer.Nature cell biology · 2015Article
- The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition.PloS one · 2015Article
- EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The interaction between stromal cells and tumor cells is emerging as a critical aspect of tumor progression. Yet there is a paucity of molecular markers for cells participating in such interactions, and only few genes are known to play a critical role in this process. Here, we describe the identification of ADAM12 (a disintegrin and metalloprotease 12) as a novel marker for a subpopulation of stromal cells that are adjacent to epithelial tumor cells in three mouse carcinoma models (models for prostate, breast and colon cancer). Moreover, we show that ADAM12 is essential for tumor development and progression in the W10 mouse model for prostate cancer. These results suggest that ADAM12 might be a useful marker for stromal cells in mouse tumors that are likely to participate in stromal/tumor cell crosstalk, and that ADAM12 is a potential target for design of drugs that prevent carcinoma growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.